XML 24 R37.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2014
Segment Reporting [Abstract] |
Summary Of Segment Performance |
|  | For the Three Months Ended September 30, |
|  |  | CAG |  | Water |  | LPD |  | Other |  | Unallocated Amounts |  | Consolidated Total |
2014 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 320,724 |  | $ | 25,747 |  | $ | 29,648 |  | $ | 7,404 |  | $ | - |  | $ | 383,523 |
Income (loss) from operations |  | $ | 62,608 |  | $ | 11,367 |  | $ | 3,886 |  | $ | 794 |  | $ | (6,466) |  | $ | 72,189 |
Interest expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (3,981) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 68,208 |
Provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,045 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 52,163 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 21 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 52,142 |
2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 283,843 |  | $ | 23,247 |  | $ | 25,131 |  | $ | 6,076 |  | $ | - |  | $ | 338,297 |
Income from operations |  | $ | 52,711 |  | $ | 10,414 |  | $ | 1,125 |  | $ | 612 |  | $ | 623 |  | $ | 65,485 |
Interest expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (1,007) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 64,478 |
Provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,786 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45,692 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 45,688 |
|  | For the Nine Months Ended September 30, |
|  |  | CAG |  | Water |  | LPD |  | Other |  | Unallocated Amounts |  | Consolidated Total |
2014 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 949,009 |  | $ | 71,655 |  | $ | 93,738 |  | $ | 19,446 |  | $ | - |  | $ | 1,133,848 |
Income (loss) from operations |  | $ | 188,820 |  | $ | 29,547 |  | $ | 17,669 |  | $ | 1,134 |  | $ | (11,716) |  | $ | 225,454 |
Interest expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (8,761) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 216,693 |
Provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,693 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 156,000 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 55 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 155,945 |
2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 856,617 |  | $ | 66,297 |  | $ | 81,448 |  | $ | 18,623 |  | $ | - |  | $ | 1,022,985 |
Income (loss) from operations |  | $ | 167,377 |  | $ | 28,682 |  | $ | 9,176 |  | $ | 1,888 |  | $ | (1,689) |  | $ | 205,434 |
Interest expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (2,132) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 203,302 |
Provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 58,745 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 144,557 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 144,542 |
Summary Of Revenue By Product And Service Category |
|  | For the Three Months Ended |  | For the Nine Months Ended
|  | September 30, |  | September 30,
|  |  | 2014 |  |  | 2013 |  |  | 2014 |  |  | 2013
CAG segment revenue: |  |  |  |  |  |  |  |  |  |  |  |
CAG Diagnostics recurring revenue: |  | $ | 277,957 |  | $ | 242,163 |  | $ | 818,327 |  | $ | 734,989
IDEXX VetLab® consumables |  |  | 90,971 |  |  | 76,080 |  |  | 264,405 |  |  | 230,637
VetLab service and accessories |  |  | 13,716 |  |  | 12,749 |  |  | 40,332 |  |  | 37,312
Rapid assay products |  |  | 46,777 |  |  | 43,042 |  |  | 139,329 |  |  | 133,182
Reference laboratory diagnostic and consulting services |  |  | 126,493 |  |  | 110,292 |  |  | 374,261 |  |  | 333,858
CAG Diagnostics capital - instruments |  |  | 18,040 |  |  | 19,115 |  |  | 55,508 |  |  | 55,702
Customer information management and digital imaging systems |  |  | 24,727 |  |  | 22,565 |  |  | 75,174 |  |  | 65,926
CAG segment revenue |  |  | 320,724 |  |  | 283,843 |  |  | 949,009 |  |  | 856,617
Water segment revenue |  |  | 25,747 |  |  | 23,247 |  |  | 71,655 |  |  | 66,297
LPD segment revenue |  |  | 29,648 |  |  | 25,131 |  |  | 93,738 |  |  | 81,448
Other segment revenue |  |  | 7,404 |  |  | 6,076 |  |  | 19,446 |  |  | 18,623
Total revenue |  | $ | 383,523 |  | $ | 338,297 |  | $ | 1,133,848 |  | $ | 1,022,985

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration